Literature DB >> 1323901

Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid.

G Reid1.   

Abstract

The immune stimulating complex (ISCOM) is a potent adjuvant which has the ability to induce both humoral and cellular immune reactions to protein antigens when they are physically associated with the ISCOM structure. However, in general only proteins with an exposed hydrophobic domain can associate with ISCOMs. As many soluble proteins are available as candidate subunit antigens there is a requirement for a method which promotes efficient incorporation of soluble protein into ISCOMs. Here it is demonstrated that following covalent attachment of palmitic acid, two soluble proteins, cytochrome C and ovalbumin, quantitatively incorporate into ISCOMs. ISCOMs containing ovalbumin prepared in this way have been shown to be highly immunogenic, generating humoral, delayed-type hypersensitivity and class I restricted T-cell immune responses following both parenteral and oral administration. The technique of incorporating soluble proteins into ISCOMs by covalent attachment of fatty acid should be generally applicable and extends the use of the ISCOM as an adjuvant.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323901     DOI: 10.1016/0264-410x(92)90439-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

Authors:  K J Maloy; A M Donachie; D T O'Hagan; A M Mowat
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens.

Authors:  A M Mowat; K J Maloy; A M Donachie
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

5.  Induction of cell death by saponin and antigen delivery.

Authors:  Ching-An Wu; Ya-Wun Yang
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 6.  Vaccine delivery using nanoparticles.

Authors:  Anthony E Gregory; Richard Titball; Diane Williamson
Journal:  Front Cell Infect Microbiol       Date:  2013-03-25       Impact factor: 5.293

7.  Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity.

Authors:  Lokesh Agrawal; W Haq; Carl Veith Hanson; D Nageswara Rao
Journal:  J Immune Based Ther Vaccines       Date:  2003-11-25

8.  Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.

Authors:  Jinhwan Cho; Sung In Lim; Byung Seop Yang; Young S Hahn; Inchan Kwon
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

Review 9.  Nanoparticle Vaccines Against Infectious Diseases.

Authors:  Rashmirekha Pati; Maxim Shevtsov; Avinash Sonawane
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

10.  Veterinary vaccines.

Authors:  L A Babiuk; A A Potter
Journal:  Biotechnol Adv       Date:  1994       Impact factor: 14.227

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.